Taysha Gene Therapies, Inc. Cash Equivalents, at Carrying Value
Taysha Gene Therapies, Inc. (TSHA) had Cash Equivalents, at Carrying Value of $317.10 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2026-03-19
- 2025-12-31: Cash Equivalents, at Carrying Value $317.10M.
- 2024-12-31: Cash Equivalents, at Carrying Value $138.30M.
- 2023-12-31: Cash Equivalents, at Carrying Value $142.40M.
- 2022-12-31: Cash Equivalents, at Carrying Value $0.00.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2025-12-31 | $317.10M 10-K · filed 2026-03-19 |
| 2024-12-31 | $138.30M 10-K · filed 2026-03-19 |
| 2023-12-31 | $142.40M 10-K · filed 2025-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-19 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |